Emivirine
Overview of the antiretroviral drug Emivirine
Emivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that was investigated for the treatment of HIV/AIDS. Although it showed promise in early studies, it was never marketed.
Mechanism of Action[edit | edit source]
Emivirine works by inhibiting the activity of reverse transcriptase, an enzyme crucial for the replication of HIV. By binding to the reverse transcriptase enzyme, emivirine prevents the conversion of viral RNA into DNA, thereby halting the replication process of the virus within the host cells.
Development and Clinical Trials[edit | edit source]
Emivirine was developed in the 1990s and underwent several clinical trials to assess its efficacy and safety in treating HIV infection. Despite initial positive results, further studies revealed limitations in its effectiveness compared to other available NNRTIs, leading to the discontinuation of its development.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of emivirine includes its absorption, distribution, metabolism, and excretion. Emivirine is orally bioavailable and is metabolized primarily in the liver. The drug's half-life and clearance rates were studied to optimize dosing regimens during its clinical evaluation.
Side Effects[edit | edit source]
Like other NNRTIs, emivirine was associated with certain side effects. Common adverse effects included rash, nausea, and headache. More severe side effects were rare but included hepatotoxicity and hypersensitivity reactions.
Comparison with Other NNRTIs[edit | edit source]
Emivirine was compared with other NNRTIs such as efavirenz, nevirapine, and delavirdine. While it shared a similar mechanism of action, emivirine did not demonstrate superior efficacy or safety, which contributed to its lack of approval for clinical use.
Current Status[edit | edit source]
As of now, emivirine is not used in clinical practice and is not available on the market. Research and development efforts have shifted towards other antiretroviral agents with better efficacy and safety profiles.
Related pages[edit | edit source]
Emivirine[edit | edit source]
Emivirine
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
